BioBridgeX
Log inCompare quotes
IND-Enabling

Regulatory Affairs & Consulting CRO & CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Regulatory Affairs and Consulting is the strategy and document work that turns your data package into an IND or CTA the FDA or EMA will accept. You need it as nonclinical and CMC studies wrap and you plan the pre-IND meeting. On BioBridgeX, source and compare qualified CRO and CDMO regulatory vendors under one contract, free for buyers.

Regulatory Affairs & Consulting CRO & CDMO vendors on BioBridgeX

We are qualifying and publishing Regulatory Affairs & Consulting CRO & CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is Regulatory Affairs and Consulting, and when do you need it?

Regulatory affairs is the discipline that translates your science into a submission a health authority will accept, and the strategy that decides how and when you talk to them. In practice it covers regulatory strategy (which agency, which pathway, what to ask for), interaction management (pre-IND and Type B meetings with the FDA, scientific advice with the EMA, briefing books and meeting minutes), authoring and review of the submission modules, and the publishing and validation that produce a compliant eCTD package. Most early companies buy this rather than build it, because the people who have run dozens of INDs sit at consultancies, not in a six-person biotech.

The need usually crystallizes nine to twelve months before you want to dose the first patient. Your GLP toxicology, safety pharmacology, and DMPK work is finishing, your CMC group has a drug substance and drug product process with stability on the way, and someone has to assemble all of it into Modules 1 through 5 and write the clinical protocol summary that makes the case the drug is safe to test. The single highest-value moment is the pre-IND meeting: a good regulatory lead frames the questions so the agency tells you whether your tox package, starting dose, and proposed clinical plan will fly, before you spend the money to find out the hard way.

This is also where the CRO and CDMO worlds meet. Pure regulatory consultancies handle strategy, agency interactions, and submission authoring across all modules. CDMOs and their CMC-regulatory groups own Module 3 (the chemistry, manufacturing and controls section) because they ran the process and hold the analytical data. Many programs use both: a strategy lead who owns the IND and a CMC-regulatory writer embedded with the manufacturer. On BioBridgeX you can source either side, or a vendor that does both, and contract once across them.

What does a Regulatory Affairs and Consulting CRO actually do?

The scope is broader than "writing the IND," and it helps to know what you are actually buying so you can scope the statement of work and avoid paying twice for the same activity.

  • Regulatory strategy and gap analysis: map your target product profile to a development and filing plan, then audit the existing data package against ICH and agency expectations to find the holes before the agency does.
  • Agency interactions: prepare the pre-IND or scientific-advice briefing book, draft the questions, run the rehearsal, attend the meeting, and capture and circulate official minutes with an action list.
  • IND and CTA assembly: author or quality-review Module 2 summaries (the nonclinical and clinical overviews), the Module 1 administrative forms, the investigator's brochure, and the protocol synopsis, then compile Module 3 CMC content with the manufacturer.
  • eCTD publishing and validation: build the submission in the electronic Common Technical Document format, run technical validation against agency rules, manage the ESG gateway transmission, and maintain the lifecycle as you file amendments.
  • Designations and expedited pathways: assess and file for Orphan Drug Designation, Fast Track, Breakthrough Therapy, RMAT, or rare pediatric disease, and advise on whether the data supports the ask.
  • Ongoing maintenance: handle IND annual reports, safety reporting timelines, protocol amendments, and the parallel EMA or other-region filings if you are running a multi-region program.

How do you choose a Regulatory Affairs and Consulting CRO?

Regulatory is a judgment business more than a throughput business, so the selection criteria differ from a lab vendor. You are buying the experience of specific people and a track record of submissions that were accepted on first pass. Work through this checklist when you compare vendors on BioBridgeX.

  • Quality and GxP posture: confirm experience with ICH guidelines (M4 for the CTD, the relevant Q and S series) and that any CMC-regulatory partner works to GMP and can stand behind Module 3 data. Ask how they handle data integrity and document control.
  • Capacity and lead time: a pre-IND meeting request and the IND itself have fixed agency clocks. Ask who specifically is staffed on your program, not just the firm's headcount, and confirm they can hit your filing date.
  • Modality and indication fit: a small-molecule oncology IND, a cell or gene therapy with an OTAT review division, and a biologic are different regulatory animals. Make sure the team has filed your modality in your therapeutic area recently.
  • Region and agency track record: ask for their FDA, EMA, MHRA, or other-region history, the number of recent INDs or CTAs filed, and how often they received a clinical hold or major information request. Recency matters because guidance and division expectations shift.
  • Data quality and submission readiness: a strong vendor builds the gap analysis first and tells you what is missing, rather than papering over a thin package. Probe how they would handle a known weak point in your data.
  • IP and confidentiality: your briefing book, protocol, and CMC details are sensitive. Confirm the NDA, conflict-of-interest checks against competing programs, and how they segregate your information from other clients.

Frequently asked questions

What is the difference between a regulatory consultancy (CRO) and a CDMO's regulatory group?
A regulatory consultancy owns the overall strategy, the agency interactions, and the authoring of the nonclinical and clinical summaries (Modules 2, 4, and 5) plus the administrative Module 1. A CDMO's regulatory group focuses on Module 3, the CMC section, because they ran the manufacturing process and hold the analytical and stability data. Most IND programs need both. On BioBridgeX you can source a strategy-led CRO, a CMC-regulatory group inside a CDMO, or a vendor that covers both, and put them under one contract.
How long does it take to prepare and file an IND with a consultant?
Once your pivotal GLP tox and CMC data are in hand, assembling and authoring a typical IND runs a few months, with eCTD publishing and validation adding time at the end. The longer pole is usually the pre-IND meeting: agencies schedule those weeks out, so most teams engage a regulatory vendor six to twelve months ahead. The cleaner your data package and the earlier the gap analysis, the shorter the back end. Timelines vary by modality and how complete your starting package is.
Do I need a pre-IND meeting, and can a consultant run it for me?
A pre-IND meeting is not mandatory, but for a first IND it is almost always worth it. It is your chance to confirm with the agency that your tox package, proposed starting dose, and clinical plan are acceptable before you commit. An experienced regulatory consultant prepares the briefing book, frames the questions so the answers are actually useful, runs a rehearsal, attends, and produces official minutes with an action list. That meeting prep is one of the most common scopes buyers source on BioBridgeX.
Can the same vendor file in both the US (FDA) and Europe (EMA)?
Many regulatory consultancies handle parallel FDA INDs and EMA or MHRA CTAs, and the CTD structure is shared across regions, which helps. The regional differences live in Module 1, the clinical trial application formats, and agency-specific expectations, so confirm the vendor has recent filings in each region you care about. If you are running a multi-region first-in-human study, ask how they sequence the filings and manage divergent agency feedback.
What does BioBridgeX charge buyers for sourcing a regulatory vendor?
Nothing. BioBridgeX is free for buyers. You source and compare qualified CRO and CDMO regulatory vendors, get matched, and review proposals at no cost. BioBridgeX acts as the neutral vendor of record and charges the vendor a flat 2% fee, so the platform stays neutral and you pay only for the regulatory work itself. You also get one contract, one PO, and one invoice even when a program uses several vendors.
Should regulatory strategy come before or after my nonclinical studies?
Before, ideally. The most expensive regulatory mistakes are designed into the data package early: the wrong tox species, a study that is not GLP when the agency expects it to be, or a starting-dose justification the division will not accept. Bringing a regulatory lead in while you are still planning IND-enabling studies, or at least early enough to shape the pre-IND questions, is far cheaper than discovering a gap after the data is locked. A good vendor will run a gap analysis up front for exactly this reason.

Source Regulatory Affairs & Consulting with one contract

Compare transparent quotes from qualified Regulatory Affairs & Consulting CRO & CDMO vendors, then contract once. Free for buyers.

Compare quotes